Humatrope ® (somatropin)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Humatrope Summary of Product Characteristics (SmPC)

HUMATROPE® (somatropin): Use in Patients With COVID-19 (Coronavirus disease 2019)

The use of somatropin in patients with COVID-19 has not been studied.

Use of Humatrope (somatropin) in a Patient With COVID-19

COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1

Lilly has not studied the use of Humatrope in patients with COVID-19 nor in patients at risk of contracting COVID-19.

Growth hormone should not be initiated to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or to patients having acute respiratory failure. 2

Dyspnoea has been reported in somatropin clinical trials and post-marketing spontaneous reports in 1%-10% of adults.2

Clinicians should use their clinical judgment in determining the most appropriate approach in treating a patient with Humatrope who has confirmed or suspected COVID-19.

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to

References

1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2. Humatrope [summary of product characteristics]. Eli Lilly and Company Limited, Hampshire.

3. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19

4. COVID-19 INFORMATION FOR CHILDREN AND ADOLESCENTS LIVING WITH ENDOCRINE CONDITIONS, INCLUDING TYPE 1 DIABETES MELLITUS https://www.eurospe.org/news/item/14064/COVID-19-information-for-children-and-adolescents-living-with-endocrine-conditions-including-type-1-diabetes-mellitus Accessed March 26, 2020

5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china

Glossary

COVID-19 = coronavirus disease 2019

ECDC = European Centre for Disease Prevention and Control

ESPE = European Society for Paediatric Endocrinology

EU WHO = World Health Organization (European regional office)

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

Date of Last Review: March 17, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question